CIWA You Know About Adjunctive Therapies for Alcohol Withdrawal

New Orleans, LA US
March 3, 2022

The purpose of this activity is to equip pharmacists and pharmacy technicians with information to help determine how to provide safe and effective adjunctive therapy options for the patients with AWS. Benzodiazepine agents have been used as the standard of care for the prophylaxis and treatment of all phases of AWS. While most patients suffering from AWS will respond to benzodiazepines, there is a subgroup of patients with severe AWS who are refractory and require additional therapies. Additionally, benzodiazepines have drawbacks including significant cognitive and neurological side effects. Recent literature has shown that using a multimodal approach to managing benzodiazepine-refractory patients appears beneficial in improving symptoms. This presentation reviews several clinical trials evaluating the use of adjunctive therapies for patients with AWS. Understanding the place for adjunctive therapies in the management of patients with AWS will allow pharmacists to provide evidence-based recommendations to the medical team.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Differentiate between the stages of acute alcohol withdrawal
  2. Discuss the severity of alcohol withdrawal and its potential complications
  3. Analyze the recent literature evaluating the use of adjunctive therapies for alcohol withdrawal
  4. Design an appropriate drug regimen for the treatment of refractory alcohol withdrawal based on patient specific factors

Pharmacy technician learning objectives

  1. Identify medications used for the treatment of alcohol withdrawals on a patient’s medication list
  2. Recognize common dosing instructions for medications used for the treatment of alcohol withdrawal
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Course opens: 
Course expires: 
Event starts: 
03/03/2022 - 12:00pm CST
Event ends: 
03/03/2022 - 1:00pm CST
Ochsner Health System
1514 Jefferson Hwy
New Orleans, LA 70121
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose.
The presenter will discuss off-label use of drugs
Planning committee members
Katherine Jennings, PharmD, BCCCP
Clinical Critical Care Pharmacist
Ochsner Medical Center
Miranda Lackie, PharmD, BCCCP
Clinical Critical Care Pharmacist
Ochsner Medical Center
Marissa Janusek, PharmD, BCPS, BCTX
Clinical Transplant Pharmacist
Ochsner Medical Center
Ziying Zhao, PharmD
PGY-1 Pharmacy Resident
Ochsner Medical Center



Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Health System. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-22-116-L01-P
Universal Activity Number: JA0006103-9999-22-116-L01-T

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
Please login or register to take this course.